Author - Rutuja Chavan

Via Negativa-What Should Fund Investors Not Do?

Fund investors spend a great deal of time deliberating the positive steps they can take to achieve better investment results. While this is an important endeavor, there is something easier and more effective that should come first – deciding what they should not be doing.

Nassim Nicholas Taleb highlighted the benefits of eliminating errors in his book ‘Anti-Fragile’ where he describes the theological idea of “via negativa”, which is a means of explaining God by what it is not, rather than what it is. Taleb broadened this concept to contend that it is easier and more beneficial to stop negative activities than to attempt to identify new, and constructive behaviors.

Investors can eliminate the mistakes that they know are damaging and costly far more easily than discovering positive behaviors that might improve their fortunes. The more complex and unpredictable the environment, the more likely this is to be true.

This is an approach that should be adopted by fund investors, who face an immeasurable line-up of choices and decision points. Rather than obsessing over how to define the precise allocation to the right funds at the right time – an incredibly difficult task – it would be more productive to first concentrate on the actions investors should avoid. Prioritize omission over commission.

So, what is it that fund investors should not do?

1) Don’t buy into a fund after an extremely positive performance: Abnormally strong performance on the upside is highly unlikely to persist, investing after a spell of stellar returns is an asymmetric bet.

2) Don’t be concentrated by the fund, manager, style, or asset manager: Concentration is the surest path to severe losses, it implies investors know far more about the future than they do.

3) Don’t predict short-term market movements: Investors cannot predict the short-term behavior of markets or funds that invest in them. Hence, they should avoid basing their decisions on expected short-term market movements.

4) Don’t check short-term fund performance: Short-term fund performance is typically nothing more than random noise, checking it frequently encourages poor decisions.

5) Don’t use performance screens: Using performance screens will highlight the funds which have done well historically. As fund performance tends to mean revert, the Author cannot think of a worse idea than to filter funds based on historic returns.

6) Don’t keep selling underperforming funds to buy outperforming funds: This is a common behavioral trait that makes investors feel good at the time of doing it, but compounds into a detrimental tax.

7) Don’t buy thematic funds based on strong back-tests: If a fund is being launched based on an in-vogue theme with a stellar back-test the chances are investors are already too late.

8) Don’t invest in active managers if one cannot bear long spells of poor performance: Even skillful active managers will underperform for long periods, if that is unappealing, invest in index funds.

9) Don’t invest in funds if one does not understand how they make money: Investing in things investors don’t understand is a recipe for disaster.

10) Don’t persist with active managers when they start doing something different: The circle of competence for active managers is usually incredibly narrow, if they are venturing outside of that, investors should avoid them.

Source: www. behaviouralinvestment.com by Joe Wiggins

Asset Multiplier Comments:

  • Each of these prohibitions attempts to establish a simple investing process that can be effective during highly uncertain environments which especially creates a lot of unnecessary noise.
  • Putting a stop to hasty decisions is as important as embracing positive investing actions. These will ensure that investors’ capital is protected and the process of wealth creation does not get hampered.

Disclaimer: “The views expressed are for information purposes only. The information provided herein should not be considered as investment advice or research recommendation. The users should rely on their own research and analysis and should consult their own investment advisors to determine the merit, risks, and suitability of the information provided.”

Business to focus on the non-covid segment  – Dr Lal PathLab

Update on the Indian Equity Market:

On Thursday, NIFTY settled 170 points lower at 17,639 (-0.9%). ADANIPORTS (-3.5%), TITAN (-3.3%), and HDFC (-2.8%) were the top losers. AXISBANK (+2.3%), DIVISLAB (+1.7%), and HINDUNILVR (+1.3%) were the gainers. Among the sectors, OIL&GAS (-2.2%), CONSUMER DURABLES (-1.7%), and METAL (-1.7%) led the losers HEALTHCARE INDEX (+0.6%), PHARMA (+0.4%), and REALTY (+0.03%) were the only gainers.

Excerpts of an interview with Mr. Om Manchanda, Managing Director, Dr Lal PathLabs. (LALPATHLAB) with CNBC-TV18 on 6th April 2022:

  • COVID cases have declined sharply over the last two months. LALPATHLAB’s business is expected to remain focused on non-COVID. If this is the way things move, the entire industry will have to deal with the COVID base in the previous year’s business.
  • LALPATHLAB is looking at multiple growth triggers, one of which is geographical expansion. They recently acquired a lab in Mumbai and are looking at expanding their footprint in the West zone. They are also expanding their organic footprint in South India.
  • The second growth trigger would be a hypothesis that wellness testing will tend to increase. Once things become stabilized, they will focus on wellness testing
  • Revenue per patient has been highly volatile in the last two years because the test mix has been different on a quarter-on-quarter basis. During the second wave, they saw COVID-alike tests going up so the revenue per patient was very high.
  • Pricing of COVID testing has been falling sharply. Initially, it was about Rs 4,000-4,500 and now it is hovering around an average of Rs 500-600 per test. This has impacted revenue per patient every quarter. LALPATHLAB’s revenue per patient for non-COVID has been around Rs 700 for many years. As they have always been dependent on volume growth more than pricing growth, they expect revenues to stabilize around Rs 700 per patient if there is no covid business further.
  • They had a structured transaction where they were waiting for FY22 to get over. Now that it has ended, LALPATHLAB will get a little more aggressive in Direct-to-Consumer activities in Mumbai as well as the West zone.
  • As of now, the Suburban brand after the acquisition is to be kept separate and LALPATHLAB will continue to focus and leverage the Suburban franchise in Mumbai.
  • Companies in this space have found it difficult to grow organically in non-core markets. So many of the regional players have grown in their core markets for them to grow faster from here on especially on a higher base. One will have to resort to inorganic growth as there is no other option.
  • FY23 will be a crucial year for stabilization as the FY21 and FY22 numbers are not correct representatives of the numbers. The inorganic component of driving growth is expected to continue for large companies.
  • Competitive intensity has gone up in the last two years as many players have entered this space. Earlier there used to be traditional business models but now the market has evolved in multiple directions after the pandemic.
  • There are now aggregators, companies with full-stack offerings where they do pharmacy, diagnostics, and even hospitals have become aggressive on retail pathology. So overall, the competitive intensity has gone up in the last two years and how these companies perform financially remains to be seen since there has been a lot of air cover due to covid in the last two years.
  • How this all pans out in the first six months of FY23 remains to be seen.

Asset Multiplier Comments

  • We expect operating leverage to be one of the synergies created out of the suburban acquisition lab in Mumbai.
  • We expect LALPATHLAB’s established brand identity in organized diagnostics to aid cost efficiencies and economies of scale.
  • We expect multiple growth levers such as the shift from unorganized to organized business, and volume growth in the non-COVID segment through organic and inorganic routes to aid revenue growth and improve margin trajectory.

Consensus Estimate: (Source: market screener websites)

  • The closing price of LALPATHLAB was ₹ 2,835 /- as of 07-April-2022. It traded at 59x/ 50x the consensus earnings estimate of ₹ 48/ 57- per share for FY23E/FY24E respectively.
  • The consensus target price of ₹ 3,090 /- implies a P/E Multiple of 54x on the FY24E EPS estimate of ₹ 57/-

Disclaimer: “The views expressed are for information purposes only. The information provided herein should not be considered as investment advice or research recommendation. The users hshould rely on their own research and analysis and should consult their own investment advisors to determine the merit, risks, and suitability of the information provided.”

Merged entity plans to open 200 screens per year- PVR & Inox Leisure


Update on the Indian Equity Market:

On Monday, NIFTY settled at 17,222 (+0.4%) near the day’s high of 17,232. PSU BANK (+1.2%), OIL & GAS (+0.9%), and BANK (+0.8%) were the top sectoral gainers. CONSUMER DURABLES (-0.9%), HEALTHCARE INDEX (-0.5%), and IT (-0.4%) led the sectoral losers. Among the NIFTY50 components, BHARTIARTL (+4%), COALINDIA (+2.7%), and AXISBANK (+2%) led the gainers. UPL (-2%), SBILIFE (-2%), and NESTLEIND (-1.8%) led the losers.

Film exhibitors Inox Leisure and PVR have approved a plan of merger. the combined entity will be called PVR Inox. Mr. Ajay Bijli, CMD, PVR Ltd (PVR), and Mr. Siddharth Jain, Director, Inox Leisure Ltd (INOX) explained the merger rationale in an interview with Business Standard on 28th March 2022. here are the excerpts:

  • For regulatory approvals, they have to go through the whole process- the stock exchange, Securities and Exchange Board of India (SEBI), and National Company Law Tribunal (NCLAT). The companies have been told by councils that they don’t need a Competition Commission of India (CCI) approval.
  • India has 9,500 screens and is still growing. New players are coming in and old ones are expanding. PVR and INOX will have 1,500 combined screens. From a macro angle, content is getting consumed everywhere and not just in theatres as consumer behaviors have changed. INOX and PVR are only a subset of the whole revenue pie that gets created.
  • INOX and PVR have a symbiotic relationship with their film, producers, and distributors. They require more films because, as a result of the pandemic, the majority of them have moved to OTT platforms. INOX and PVR are looking at the overall pie of the gross box office collections of India that got severely impacted.
  • They expect the revenue pie to increase if they have more screens and the full support of their stakeholders. The film fraternity is an important stakeholder for PVR and INOX and they expect to play more cinemas in theatres. They don’t intend to spoil this equation by coming together and using their pricing power.
  • In the pre-pandemic era, both companies were adding about 60-80 screens per year. They plan to increase this number to 200 per year going forward.
  • India has 9,500 screens compared to 70,000 in China. As a country, India has been adding 400 screens a year as compared to 6,000-7,000 per year in China which shows how underpenetrated the market is in our country.
  • This partnership is expected to encourage the cinema exhibition industry to continue its investments. Content creators would get encouraged as the size of the industry grows.
  • The merger process is expected to take six to nine months.
  • Smaller towns have smaller malls and shopping centers coming in. A lot of single screens are converting into two and three plexes. INOX and PVR are not against growing in any format but they would be interested to seek any opportunity that comes up organically.

Asset Multiplier Comments

  • The film exhibition sector has been one of the worst impacted sectors due to the pandemic. This has led to a majority of the films getting released on OTT platforms. The sector is expected to go back to its pre-pandemic levels on the back of new film releases and the reopening of theatres.
  • We expect revenue and cost synergies to be created out of this merger. We believe the merged entity would have improved bargaining powers in terms of rentals and advertising rates charged due to an increase in market share.
  • We expect the merged entity to ramp up screen openings over the next few years and take advantage of the underpenetrated film exhibition market in India.

Consensus Estimate: (Source: market screener website)

  • The closing price of INOX was ₹ 525/- as of 28-March-2022. It traded at 40x/ 29x the consensus earnings estimate of ₹ 13/ 18/- per share for FY23E/FY24E respectively. The consensus target price of ₹ 500/- implies a P/E Multiple of 28x on the FY24E EPS estimate of ₹ 18/-
  • The closing price of PVR was ₹ 1,883/- as of 28-March-2022. It traded at 54x/ 30x the consensus earnings estimate of ₹ 35/ 63/- per share for FY23E/FY24E respectively. The consensus target price of ₹ 1,886/- implies a P/E Multiple of 30x on the FY24E EPS estimate of ₹ 63/-

Disclaimer: “The views expressed are for information purposes only. The information provided herein should not be considered as investment advice or research recommendation. The users should rely on their own research and analysis and should consult their own investment advisors to determine the merit, risks, and suitability of the information provided.”

Confident of delivering double-digit growth for India business- Zydus Lifesciences

Update on the Indian Equity Market:

On Thursday, NIFTY settled at 17,223 (-0.1%) near the day’s high of 17,291. MEDIA (+6%), METAL (+1.5%), and IT (+1.2%) were the top sectoral gainers. PRIVATE BANK (-1.8%), BANK (-1.7%), and CONSUMER DURABLES (-1.6%) led the sectoral losers. Among the NIFTY50 components, DRREDDY (+4.7%), COALINDIA (+2%), and ULTRACEMCO (+1.8%) led the gainers. KOTAKBANK (-3%), TITAN (-2.6%), and HDFCBANK (-2.5%) led the losers.

Excerpts of an interview with Mr. Sharvil Patel, MD, Zydus Lifesciences (ZYDUSLIFE) with CNBC-TV18 on 24th March 2022:

  • In the US, the generic business has always been cyclical and it needs to be seen in a three-to-five-year window. They believe any company with a very strong portfolio and good cost management and backward integration capabilities can do well in the US market.
  • Mr. Patel believes that the US generic market is a very large opportunity that exists and the volumes are very large as well which makes it an opportunity worth taking effort for.
  • For ZYDUSLIFE, the pricing pressures are expected to continue and one has to constantly optimize costs, and build efficiencies through larger scale and backward integration. This is what ZYDUSLIFE is doing in terms of operational efficiencies as well as sourcing efficiencies.
  • In the next 18 months, ZYDUSLIFE is expected to have a very good portfolio of generic launches that will help it cross the current USD 700-800 mn revenue range that it is at and come closer to a billion-dollar revenue range.
  • Once it has a resolution for one of its facilities as well as more important launches in FY24, ZYDUSLIFE will be on an upward trajectory for its US generic business.
  • For India business, ZYDUSLIFE has taken efforts to reduce complexity both in terms of the large portfolio and the way its business units were formed. With a lot of restructuring, it is at a stage where the focus is on the top 30 molecules with the new introductions on the proprietary molecule side.
  • ZYDUSLIFE is confident about delivering better than market growth and double-digit growth for the India formulations business.
  • It is expected to produce 10 mn doses per month of the Covid vaccine ZyCov-D which means they can vaccinate about 3 mn people. ZYDUSLIFE has submitted a trial of the vaccine for the age group of 12-18 and has received a DCGI (Drugs Controller General of India) approval but is waiting for NTAGI (National Technical Advisory Group on Immunization) clearance.
  • A booster dose strategy has worked out where it has to change vaccines from the earlier vaccination to the next vaccine.
  • Even though ZYDUSLIFE is delayed by 6 months, it believes there is enough room for it to make the vaccine available with a production of 8 to 10 mn doses a month.

Asset Multiplier Comments

  • The US business is expected to ramp up in the next 18 months on the back of new launches and approvals and meet its revenue guidance of USD 1 bn. With its backward-integration capabilities and operational efficiencies, we believe ZYDUSLIFE is well placed to tackle the US pricing pressures.
  • It is working on a pipeline comprising injectables, biosimilars, NCE-led specialties, and vaccines. We expect these to contribute to ZYDUSLIFE’s growth trajectory over subsequent quarters.
  • We expect EBITDA margins to be under pressure due to increased raw material costs.

Consensus Estimate: (Source: market screener website)

  • The closing price of ZYDUSLIFE was ₹ 366/- as of 24-March-2022. It traded at 17x/ 15x the consensus earnings estimate of ₹ 21/ 24/- per share for FY23E/FY24E respectively.
  • The consensus target price of ₹ 482/- implies a P/E Multiple of 20x on FY24E EPS estimate of ₹ 24/-

Disclaimer: “The views expressed are for information purposes only. The information provided herein should not be considered as investment advice or research recommendation. The users should rely on their own research and analysis and should consult their own investment advisors to determine the merit, risks, and suitability of the information provided.”

This Week in a Nutshell (14th-18th March)

Technical talks

NIFTY opened the week on 14th March at 16,646 and ended at 17,287 on 17th March. NIFTY gained 1.8% throughout the week. The next support and resistance levels for the index would be 16,711 and 17,380 respectively.

All the sectoral indices gained this week, with Financial Services  (+6.8%), Bank (+5.7%), and Auto (+5.6%) being the gainers.

Weekly highlights

  • The retail inflation rate in India – measured by the Consumer Price Index (CPI)- came in at 6.07% in February 2022 as compared to 5.93% in February 2021. Commodity prices are expected to remain at elevated levels due to the geopolitical tensions disrupting supply chains and rising costs.
  • Russia-Ukraine update: Ukraine has warned that peace negotiations could last for weeks and said evacuations of combat zones continued, with another 5,000 people leaving Mariupol. Russia repeated a threat to target arms convoys sent by the US and its allies.
  • After losing ground for 5 consecutive days in the hopes of Russia-Ukraine coming to some sort of agreement, WTI crude settled above US$100/barrel on 18th March after negotiations between Russia and Ukraine deteriorated. Oil prices are expected to remain volatile till there’s some resolution on what Russia’s ultimate goal is.
  • The Federal Reserve on Wednesday raised interest rates by 25bps for the first time since 2018 and laid out an aggressive plan to push borrowing costs to restrictive levels. Investors in the US seemed to shrug off the initial jitters of the rate hike as Feds Chair Jerome Powell said the economy is strong enough to weather the rate hikes and maintain its current strong hiring and wage growth.
  • The Bank of England on Thursday hiked its main interest rate to its pre-pandemic level by 0.25%, the third increase in a row, to battle decades-high inflation. K. inflation hit a 30-year high in January and is expected to rise further as Russia’s invasion keeps energy prices high.
  • NASDAQ (+2%) and S&P500 (+1%) rallied for the fourth consecutive session on Friday as Fed met market expectations by starting its rate-hiking cycle on Wednesday.
  • The foreign institutional investors (FII) turned buyers this week and bought equities worth Rs 16,860 mn. Domestic institutional investors (DIIs) continued to be buyers and bought equities worth Rs 12,900mn.

Things to watch out for next week

  • The geopolitical tensions between Russia and Ukraine are expected to continue impacting supply chains, high commodity prices, and volatility in crude oil prices.
  • In India, the next few weeks are expected to be quiet on the corporate front as companies will be in a silent period before the announcement of the FY22 earnings.

Disclaimer: “The views expressed are for information purposes only. The information provided herein should not be considered as investment advice or research recommendation. The users should rely on their own research and analysis and should consult their own investment advisors to determine the merit, risks, and suitability of the information provided.”

Container unavailability is a serious challenge going forward- Vinati Organics

 

Update on the Indian Equity Market:

On Wednesday, NIFTY50 ended in green at 16,345 (+2%). Among the sectoral indices, MEDIA(+4%), REALTY(+2.9%), and AUTO (+2.8%) were the top gainers, whereas METAL (-0.4%), was the only loser. Among the stocks, ASIANPAINT (+6%), RELIANCE (+5.5%), and BAJFINANCE (+5%) were the top gainers while SHREECEM (-2.6%), ONGC (-2.5%), and POWERGRID (-2%) led the losers.

Excerpts of an interview with Ms. Vinati Saraf Mutreja, MD, Vinati Organics (VINATIORGA) with CNBCTV18 on 8th March 2022:

  • Raw materials come from refineries and are crude dependent. As crude prices increase, VINATIORGA’s raw material prices will also increase. It has a pass-through clause for most of its products as they have formula-based pricing and can pass on these raw material price hikes to its customers to a certain extent.
  • Exporters like VINATIORGA are facing logistical issues like the unavailability of containers and this is expected to be a serious challenge going forward.
  • On a positive note, VINATIORGA is witnessing good demand. Its main product Acrylamide Tertiary-butyl Sulfonic acid (ATBS) which is used in oil and gas and oil drilling is witnessing positive demand from North America and Europe.
  • Ibuprofen which was very slow last year has started picking up. Butyl Phenol is also experiencing a breakthrough in the market.
  • Ms. Mutreja expects the EBITDA margins to be maintained between 28-30%. EBITDA per kilogram remains more or less constant because of the formula pricing. It sometimes does not necessarily capture some of the fixed expenses like utility costs, fuel costs, overheads, and general inflation. These expenses get hedged as capacities get expanded and utilization levels improve owing to better demand.
  • VINATIORGA saw very high logistics costs in CY21 which eventually started tapering down by Dec-21-Jan 22. After the Russia-Ukraine war started in February, the costs have gone up again. Obtaining bookings and container availability has become a challenge for the entire industry, especially in North America, Europe, and Southeast Asia.
  • Costs have gone up 20-30% for US and Europe bookings in Jan-Feb 22.
  • VINATIORGA is foraying into the production of niche chemicals through Veeral Organics (a subsidiary) at a total capex of Rs 2,500 mn. It involves different products one of which has application in the fragrance industry, one is used as a polymer additive, one is used in the pharmaceutical industry. This is a greenfield project and is expected to be completed in 15 months. Total revenue of Rs 3,000 mn is expected from this project.
  • Veeral Additives is another project which is a merger with VINATIORGA. It is subject to NCLT approval which is causing some delay. This anti-oxidants plant which is used in resins and plastics is expected to come on stream later in March-22.

Asset Multiplier Comments

  • Earlier, customers had stocked Ibuprofen due to Covid-19 related concerns. Due to the lower-than-expected consumption and higher inventory, demand for IBB has also reduced. The demand for IBB may pick up again from March 2022.
  • The new capex for Veeral Organics involves the manufacturing of five new products. The company may target 10% of the total market size of Rs 25 bn.
  • The headwinds of high raw material costs and higher logistic costs may keep the company’s margins under pressure for the next 2 quarters. We expect the EBITDA margins to normalize back to around 30% level by September 2022. 

Consensus Estimate: (Source: Marketscreener and Investing.com websites)

  • The closing price of Vinati Organics was ₹ 1,858/- as of 08-March-2022. It traded at 58x/42x/33x the consensus earnings estimate of ₹ 32/44/56 for FY22E/FY23E/FY24E respectively.
  • The consensus target price of ₹ 2,052/- implies a P/E multiple of 36x on FY24E EPS estimate of ₹ 56/-

Disclaimer: “The views expressed are for information purposes only. The information provided herein should not be considered as investment advice or research recommendation. The users should rely on their own research and analysis and should consult their own investment advisors to determine the merit, risks, and suitability of the information provided.”

Price hikes make sense when loss ratios are moving up- Bajaj Allianz General Insurance


Update on the Indian Equity Market:

On Thursday, NIFTY closed in the red at 16,498 (-0.6%). Among the sectoral indices, OIL & GAS(+1.5%), IT (+1.2%), and METAL (+1.2%) closed higher while AUTO (-2.3%), CONSUMER DURABLES (-1.3%), OIL & FINANCIAL SERVICES 25/50 (-1.3%) closed lower. Among the stocks, ONGC (+4.6%), UPL (+4.5%), and POWERGRID (+2.8%) were the top gainers while ULTRACEMCO (-6.7%), ASIANPAINT (-5.2%), and HDFCLIFE (-5%) were among the top losers.

Excerpts from an interview of Mr. Tapan Singhel, MD & CEO of Bajaj Allianz General Insurance (BAGIC) in Business Standard dated 3rd March 2022:

  • During the third wave in January 2022, claims moved up 241 percent compared to December 2021 but the severity and hospitalization were low as compared to the second wave. The claim ratio did move up but not as much as it did in the second wave.
  • COVID claims contributed 20% to the overall claim ratio. The company has settled COVID-related claims of over Rs 8,000 mn since April 2020.
  • There was a 20 percent movement in BAGIC’s loss ratios. They were the only ones to make underwriting profits in CY21 but COVID-19 still impacted the profitability of the business. There was some relief in the motor segment as the claim ratios declined during the pandemic.
  • BAGIC would have considered increasing its premiums had COVID-19 been a regular phenomenon.
  • Mr. Singhel worries about the rising medical inflation which has gone up 30-45 percent in the last three years from a typical range of 10-15 percent. He also pointed out the need to have regulators for hospitals to control hospital bill inflation and a reduction in GST of 18% on premiums.
  • The premiums on group health policies have gone up due to price hikes taken to manage increasing loss ratios in that segment. In retail health, companies can take price hikes only after three years. During the pandemic, many consumers purchased covid- related products. Overall, on a base effect, growth in retail seems lower.
  • The insurance industry has a direct correlation with the volumes of vehicles being sold. The semiconductor shortage has caused sales volumes to decline resulting in muted growth in motor insurance premiums.
  • Hikes in motor third-party premiums will be taken when loss ratios start moving up in this segment. The industry seems comfortable with the existing situation.
  • As infrastructure is the main focus of our country, Mr. Singhel believes there should be solutions to provide funding to contractors and free up their capital. He believes surety bonds to be a very good move by the regulator and the government and that BAGIC will be keeping an eye on this business. The idea is to not replace bank guarantees entirely.
  • BAGIC is sure that any acquisition they do would be adding value to the company, in terms of distribution or processes.

Asset Multiplier comments:

  • We expect the health claims ratio to moderate from its peak levels that were observed during the pandemic.
  • With economic activities picking up, we believe BAGIC is well placed to maintain its combined ratio at pre-covid levels over FY23 and 24.
  • Improvements in operating efficiencies and moderation in claims ratio are expected to improve BAGIC’s profitability over the subsequent quarters.

Consensus Estimate: (Source: Market screener website)

  • BAGIC is a subsidiary of Bajaj Finserv Ltd. The closing price of Bajaj FInserv was ₹ 15,704 as of 3-March-2022. It traded at 6.4x/5.5x/4.7x the consensus book value per share estimate of ₹ 2,452/ 2,848/ 3,326/ for FY22E/FY23E/FY24E respectively.
  • The consensus average target price is ₹ 16,341/- which implies a PE per share multiple of 4.9x on FY24E BVPS of ₹ 3,326/-.

Disclaimer: “The views expressed are for information purposes only. The information provided herein should not be considered as investment advice or research recommendation. The users should rely on their own research and analysis and should consult their own investment advisors to determine the merit, risks, and suitability of the information provided.”

Economic activity and business expected to pick up – Muthoot Finance

 

 

 

 

 

 

 

 

Update on the Indian Equity Market:

On Tuesday, NIFTY ended at 17,352 (+3%), near its high of 17,372. Among the sectoral indices, AUTO(+4%), PSU BANK (+4%), MEDIA (+3.7%) were the top gainers and there were no losers today. Among NIFTY 50 constituents, TATAMOTORS (+6.7%), BAJFINANCE (+5.6%), and EICHERMOT (+5.5%) were the top gainers while CIPLA (-3.6%) and ONGC (-1%) were the only losers today.

MUTHOOTFIN declared 3QFY22 quarterly results. Following are the excerpts from an interview with Mr. George Alexander Muthoot, MD, Muthoot Finance (MUTHOOTFIN) with The Economic Times on 14th February 2022:

  • Despite getting hit by back-to-back covid waves, MUTHOOTFIN was able to increase its disbursals. The company’s focus was mainly on collections because the loans that they had given earlier were becoming stage three assets. These had to be taken back by the customers and those who did not take back had to be auctioned.
  • Disbursals saw an increase but there were repayments as well so the overall growth has been flat. MUTHOOTFIN was able to maintain its profit for the year.
  • As for the road ahead, the Company expects the economic activity to pick up. MSME, small traders, and businessmen are their main customers. As things start opening up in Kerala, more business is expected.
  • Muthoot expects the cost of funds to go up by 50 bps over the next 5-6 months. He is sure about costs remaining low and not going back to higher rates that were prevalent two years back. MUTHOOTFIN has been able to solve a good percentage of its borrowing cost to their customers to keep them satisfied because their businesses are also not doing that well.
  • MUTHOOTFIN will continue to support its customers and expects to see some growth in the business environment over the next few quarters.
  • As a result of MUTHOOTFIN’s work over the past few decades, it has become customers’ first choice for gold loans. They are seeing more and more players entering this sector which only shows that it is a good growth sector.
  • The gold loan market is expanding as customers have started considering gold loans for their business needs and this is expected to widen the market.
  • Once the economic activities pick up, Mr. Muthoot has observed that the new players in this sector lose interest as other forms of lending also go up. MUTHOOTFIN will continue to focus entirely on gold loans unlike other players as they believe this sector to be good in good as well as bad times.
  • As gold prices inch up, customers, as well as MUTHOOTFIN, get benefitted from these increased prices. The customer becomes eligible for more loans on the same gold and if and when, the customer abandons the gold, MUTHOOTFIN’s realizations from auctions of abandoned gold are improved as prices are higher.
  • MUTHOOTFIN can maintain its book as they factor in for steady-state or even a small fall in the gold price.
  • The only digital strategy that MUTHOOTFIN uses is digital interest payments, making top-ups or repaying the money. Customers are acquired digitally but they are required to give the collateral physically and then obtain loans or physically go to the branch to take back their gold.

Asset Multiplier Comments

  • Despite NPAs increasing since the last few quarters, MUTHOOTFIN is currently in a position to auction this gold and recover much better as gold prices have started going up.
  • With economic activity picking up, we expect steady growth in MUTHOOTFIN’s loan book.
  • Given the increase in competition in the gold loan sector, how MUTHOOTFIN maintains its position of being the customer’s first choice remains to be seen.

Consensus Estimate (Source: Marketscreener & investing.com websites)

  • The closing price of MUTHOOTFIN was Rs. 1,354/- as of 15-February-2022. It traded at 2.9x/2.4x/2x the consensus BVPS estimates of ₹ 455/551/663 for FY22E/FY23E/FY24E respectively.
  • The consensus target price of ₹ 1,844/- implies a P/BV Multiple of 2.7x on FY24E BVPS estimate of ₹ 663/-

Disclaimer: “The views expressed are for information purposes only. The information provided herein should not be considered as investment advice or research recommendation. The users should rely on their own research and analysis and should consult their own investment advisors to determine the merit, risks, and suitability of the information provided.”

Focused on creating organic and inorganic business opportunities – IndusInd Bank


Update on the Indian Equity Market:

On Tuesday, NIFTY closed in the green at 17,266 (+0.3%) near its high of 17,300. Among the sectoral indices, PSU BANK (+0.8%), METAL (+0.8%), and PHARMA (+0.5%) were the top gainers and MEDIA (-1%), REALTY (-0.8%) and IT (-0.3%) were the sectoral losers. TATASTEEL (+3%), CIPLA (+2.0%), and RELIANCE (+1.7%) were the top gainers. ONGC (-2.8%), POWERGRID (-1.8%), and SBILIFE (-1.3%) were among the top losers.

Excerpts from an interview of Mr. Sumant Kathpalia, MD & CEO, IndusInd Bank (INDUSINDBK) with Economic Times dated 07th February 2022:

  • INDUSINDBK had slowed down their microfinance business and hence the disbursements grew only by 3% sequentially. Disbursement growth came at 4.5% without microfinance as always guided by the company.
  • On deposits, they are as good as the industry and are very comfortable with the way the growth is coming back.
  • Microfinance currently holds 12.5% of INDUSINDBK’s portfolio. It has guided about the proportion being limited to 15% of the total portfolio. It has diversified the rural vertical into various other businesses and is growing rapidly in the merchant acquiring business.
  • The deep rural book that is of ₹ 1500 mn currently, is expected to reach a value of ₹ 5,000 mn by the end of FY23E.
  • INDUSINDBK has launched a new platform with a focus on five verticals. Out of these, easy credit for personal loans and credit cards are already launched. It is in the market since January and the company is seeing a rapid increase in disbursements as well as the experience the clients are getting in it.
  • They have launched ‘Indus Wheels’ which specifically focuses on vehicle finance and they expect to see a different used car experience in the market from February end or March onwards.
  • INDUSINDBK has launched one or two commercials about their merchant acquiring business and saw a good response to the same. They have a few launches lined up that will be millennial prepositions, hugely interactive offering personalized user experience.
  • They have created provisions of ₹ 3,328 mn as a protection against any future shocks. They have also done a ₹ 1,400 mn provision on the restructured book.
  • The company will now lend at 230 bps and believes that the credit cost should settle around 120 to 150bps.
  • INDUSINDBK has always been interested in para-banking. They are looking to add a fourth domain which can come out of affordable housing, wealth management, mortgage, or a business like a merchant acquisition. The main objective of this domain is to create a business opportunity that can be organic or inorganic.
  • The promoters of the bank are awaiting the operating guidelines on the 26% promoter limit allowed by the RBI. Once these guidelines are clear and if the bank needs funds, the promoters will be the first ones to infuse capital into the company.
  • Vodafone-Idea business has to start playing out for INDUSINDBK to reverse its provisions. Vodafone is expected to come back to the banker’s consortium wagon with a definitive business plan about how they will raise funds and how the business is going to grow. Once that is finalised, how Vodafone’s business gets executed over two or three quarters will decide if the provisions will start reversing.
  • MSME and SME sectors are growing. On the corporate and on the MSME side, the company is confident about being ahead of the market and not an outlier.
  • Kathpalia expects the central bank will continue to support growth and the increase in rates will not be passed on to the end consumers immediately.
  • Four things to look at in FY23 for INDUSINBK: 1) Now that the balance sheet is stable, they will be focused on the bank’s growth momentum, 2) PPOP margins have been highest or second highest in the industry around 5.9% to 6% and will be maintained between 5.75% to 6%. 3) Credit costs are expected to swing back and land between 120 and 150 bps and 4) The bank’s fourth domain should come into existence in the form of para banking or affordable housing or wealth management.

Asset Multiplier comments:

  • With economic activities picking up, the disbursements in vehicle finance and microfinance are expected to start gaining momentum.
  • The bank has sufficient provisioning which is expected to reduce credit costs and improve its margin trajectory in the subsequent quarters.
  • We expect healthy traction in the bank’s loan book and an increase in disbursements due to the introduction of technology-driven services.

Consensus Estimate: (Source: Market screener and investing websites)

  • The closing price of IndusInd Bank was ₹ 938/- as of 08-February-2022.  It traded at 1.5x/1.3x/1.2x the consensus book value per share estimate of ₹ 611/688/784/- for FY22E/FY23E/FY24E respectively.
  • The consensus average target price is ₹ 1,267/- which implies a P/BV multiple of 1.6x on FY24E BVPS of ₹ 784/-.

Disclaimer: “The views expressed are for information purposes only. The information provided herein should not be considered as investment advice or research recommendation. The users should rely on their own research and analysis and should consult their own investment advisors to determine the merit, risks, and suitability of the information provided.”

New launches to offset US pricing pressure- Cipla

Update on the Indian Equity Market:

On Monday, NIFTY closed in the green at 17,339 (+1.4%) ahead of the Budget. Among the sectoral indices, REALTY (+3%), PSU BANK (+3%), and IT (+2.8%) were the top gainers and there were no sectoral losers. TECHM (+5.2%), TATAMOTORS (+4.0%), and WIPRO (+3.8%) were the top gainers. INDUSINBK (-3.5%), KOTAKBANK (-2.0%), and COALINDIA (-1.4%) were among the top losers.

Excerpts from an interview of Mr. Umang Vohra, MD & Global CEO, Cipla (CIPLA) with Economic Times dated 31st January 2022:

  • On the India growth numbers, CIPLA saw strong momentum in the base portfolio and has pre-allocated resources to the bigger brands. As healthcare begins to expand, it saw a large contribution from Tier 1 to 4 towns to the volume growth. It has re-positioned resources on its key branded franchises in India on the back of consumer business playing out strongly.
  • In the US, CIPLA’s respiratory portfolio gained market share resulting in revenues worth US$150 mn. Mr.Vohra said the December quarter always has bunched up sales because that is the buying pattern in the US as there are holidays in the first 7-8 days of January.
  • Launch momentum is going to be significant in FY23 because the US is responsive to it.
  • In South Africa, the market is divided into private and tender. The tender is linked to government buying. The private market has always shown robust growth and CIPLA has been beating the market over the past five years QoQ.
  • There were congestions in the tender market as there are patterns of government buying in response to the Budget of the country. These patterns respond to the aid that the country receives in terms of a portfolio of medicines, in terms of the buying agencies supporting the various governments.
  • The South African tender market is going through a new cycle similar to the one 3 years ago. Despite some shifts due to this cycle, it is expected to go back to the way it was originally.
  • In India, CIPLA sees doctor practice to come back strongly on the back of volume demand.
  • Pricing pressure in the US is expected to continue. It is the nature of the US market. It is a free market and prices fall as more players enter it. CIPLA has responded to these pressures quite significantly and these are expected to continue going forward.
  • The issue of pricing will be there in the US markets but new launches are expected to offset that.

Asset Multiplier comments:

  • The US business is expected to ramp up on the back of new launches and a complex generics portfolio.
  • The revenues were not impacted significantly by US price erosion due to new complex launches and increasing market share. Should the new launches get delayed, CIPLA will be impacted by the pricing pressures in the US.
  • With the decline in COVID-19 products’ contribution, the base portfolio has started growing. We expect this base portfolio to perform well in the coming quarters as the cases start declining.
  • We expect margins to sustain the upward trajectory for the next few quarters as the complex pipeline is strong.

Consensus Estimate: (Source: Market screener and Tikr websites)

  • The closing price of Cipla was ₹ 945/- as of 31-January-2022.  It traded at 27x/23x/20x the consensus earnings per share estimate of ₹ 35/42/50/- for FY22E/FY23E/FY24E respectively.
  • The consensus average target price is ₹ 1,088/- which implies a PE multiple of 22x on FY24E EPS of ₹ 50/-.

Disclaimer: “The views expressed are for information purposes only. The information provided herein should not be considered as investment advice or research recommendation. The users should rely on their own research and analysis and should consult their own investment advisors to determine the merit, risks, and suitability of the information provided.”